Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 24;61(9):e00472-17.
doi: 10.1128/AAC.00472-17. Print 2017 Sep.

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

James A Karlowsky  1 , Krystyna M Kazmierczak  2 , Boudewijn L M de Jonge  3 , Meredith A Hackel  4 , Daniel F Sahm  4 , Patricia A Bradford  3
Affiliations

In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015

James A Karlowsky et al. Antimicrob Agents Chemother. .

Abstract

The combination of the monobactam aztreonam and the non-β-lactam β-lactamase inhibitor avibactam is currently in clinical development for the treatment of serious infections caused by metallo-β-lactamase (MBL)-producing Enterobacteriaceae, a difficult-to-treat subtype of carbapenem-resistant Enterobacteriaceae for which therapeutic options are currently very limited. The present study tested clinically significant isolates of Enterobacteriaceae (n = 51,352) and Pseudomonas aeruginosa (n = 11,842) collected from hospitalized patients in 208 medical center laboratories from 40 countries from 2012 to 2015 for in vitro susceptibility to aztreonam-avibactam, aztreonam, and comparator antimicrobial agents using a standard broth microdilution methodology. Avibactam was tested at a fixed concentration of 4 μg/ml in combination with 2-fold dilutions of aztreonam. The MIC90s of aztreonam-avibactam and aztreonam were 0.12 and 64 μg/ml, respectively, for all Enterobacteriaceae isolates; >99.9% of all isolates and 99.8% of meropenem-nonsusceptible isolates (n = 1,498) were inhibited by aztreonam-avibactam at a concentration of ≤8 μg/ml. PCR and DNA sequencing identified 267 Enterobacteriaceae isolates positive for MBL genes (NDM, VIM, IMP); all Enterobacteriaceae carrying MBLs demonstrated aztreonam-avibactam MICs of ≤8 μg/ml and a MIC90 of 1 μg/ml. Against all P. aeruginosa isolates tested, the MIC90 of both aztreonam-avibactam and aztreonam was 32 μg/ml; against MBL-positive P. aeruginosa isolates (n = 452), MIC90 values for aztreonam-avibactam and aztreonam were 32 and 64 μg/ml, respectively. The current study demonstrated that aztreonam-avibactam possesses potent in vitro activity against a recent, sizeable global collection of Enterobacteriaceae clinical isolates, including isolates that were meropenem nonsusceptible, and against MBL-positive isolates of Enterobacteriaceae, for which there are few treatment options.

Keywords: Gram-negative bacteria; aztreonam-avibactam; metallo-β-lactamase; surveillance studies.

PubMed Disclaimer

References

    1. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-β-lactamases, the quiet before the storm? Clin Microbiol Rev 18:306–325. doi:10.1128/CMR.18.2.306-325.2005. - DOI - PMC - PubMed
    1. Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. 2015. In vitro susceptibility of characterized β-lactamase-producing strain tested with avibactam combinations. Antimicrob Agents Chemother 59:1789–1793. doi:10.1128/AAC.04191-14. - DOI - PMC - PubMed
    1. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55:390–394. doi:10.1128/AAC.00756-10. - DOI - PMC - PubMed
    1. Pérez A, Canle D, Latasa C, Poza M, Beceiro A, del Mar Tomás M, Fernández A, Mallo S, Pérez S, Molina F, Villanueva R, Lasa I, Bou G. 2007. Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate. Antimicrob Agents Chemother 51:3247–3253. doi:10.1128/AAC.00072-07. - DOI - PMC - PubMed
    1. Adler M, Anjum M, Andersson DI, Sandegren L. 2016. Combinations of mutations in envZ, ftsI, mrdA, acrB, and acrR can cause high-level carbapenem resistance in Escherichia coli. J Antimicrob Chemother 71:1188–1198. doi:10.1093/jac/dkv475. - DOI - PubMed

MeSH terms

LinkOut - more resources